Project Grant R21AG086850
Award Date
9/15/24
Completion Date
5/31/26
Dollars Obligated
$644K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44106, USA
Similar Awards
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,156,262.00 to Case Western Reserve University's Office of Research Administration Division (doing business as University Hospitals of Cleveland) to conduct research on the role of N6-methyladenosine (m6A) RNA modification dysregulation in the pathogenesis of Alzheimer's disease. The research aims to determine how reduced expression of the m6A methyltransferase enzyme METTL3...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $161,000.00 to Case Western Reserve University to investigate the role of RNA N6-methyladenosine (m6A) modification in regulating tau mRNA metabolism and its potential impact on tauopathies, a group of neurodegenerative diseases characterized by abnormal tau protein accumulation. The research aims to determine how depletion of the m6A methyltransferase METTL14 affects tau mRNA splicing...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to elucidate the role of RNA modification, specifically N6-methyladenosine (m6A), in the pathogenesis of Alzheimer's disease (AD) and related tauopathies. The total award amount is $745,092 over the project period from January 1, 2025 to November 30, 2029. The key objectives are to: 1) decode the epitranscriptomic profiles impacted by tau pathology using m6A DART-seq; 2) determine the role of RNA...
This Project Grant award from the National Institute on Aging's (NIA) Aging Research program (CFDA 93.866) provides $3,038,050 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to study the molecular mechanisms of Alzheimer's disease. The funded research aims to discover a novel oxidative stress pathway that targets microglia, the immune cells in the brain, leading to their dysfunction and detrimental consequences in Alzheimer's disease. The goal is to develop...
This three-year Project Grant from the National Institute on Aging, part of the Department of Health and Human Services, will fund $2,136,033 in research under the Aging Research program (CFDA 93.866). The grant recipient, Case Western Reserve University in partnership with University Hospitals of Cleveland, will investigate the role of the CHCHD6 protein in Alzheimer's disease pathology and potential therapeutic interventions. Specifically, the researchers will study the causes and consequences...
This Project Grant from the National Institutes of Health's National Institute on Aging, under the Aging Research program (CFDA 93.866), provides $4,041,438 to develop new computational tools and biomarkers for Alzheimer's disease. The University of Miami will aggregate and analyze DNA methylation datasets to identify age-associated epigenetic changes related to aging and Alzheimer's progression. Researchers will create a searchable web interface to disseminate findings on the role of DNA...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $788,900 to Case Western Reserve University to investigate the pathogenic role of the APP E590D variant in Alzheimer's disease. The key objectives are to: Identify a new C-terminal cleavage site of the amyloid precursor protein (APP) beyond the beta-secretase cleavage using a mass spectrometry approach, and Generate an APP E590D knock-in mouse model of Alzheimer's disease to test the...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will provide $802,034 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to develop a Multimodal, Multiscale and Multistage Systems Biology (M3SB) infrastructure for precision medicine in Alzheimer's disease and longevity. The key products and services to be delivered include: Multi-modal analyses of genetics, multi-omics data, cross-species protein interactome...
This $107,948 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to enhance understanding of the biological signatures that distinguish subgroups of patients with Alzheimer's disease (AD). The key goals are to: Determine if AD subtypes can be identified solely using magnetic resonance imaging (MRI)-derived features through the application of machine learning algorithms. Integrate epigenetic profiles, including small non-coding RNA expression and DNA...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will support Emory University's research into the genetic regulation of brain transcriptomics and proteomics associated with Alzheimer's disease and related dementias. The $528,876 award, effective June 1, 2025, will fund the development of new analytic tools to integrate genomic data across multiple tissues and improve the identification of genetic risk factors and underlying molecular mechanisms for...